Introdução: Acne é uma dermatose que apresenta o padrão do sebo alterado, tanto quali, quanto quantitativamente. Objetivos: Estudar as possíveis alterações quali e quantitativas dos ácidos graxos encontrados no sebo de portadores de acne vulgar graus II ou III mediante ao uso diário de limeciclina e/ou suplemento oral a base de ácidos linoleico, gamalinolênico e oleico. Métodos: Quarenta e cinco sujeitos de pesquisa masculinos, de 12 a 40 anos de idade, portadores de acne vulgar graus II ou III, submeteram-se a 90 dias de uso de: Grupo A, 300mg/dia de limeciclina; Grupo B, 540mg de ácidos gamalinolênico, 1.200mg linoleico e 510mg oleico/dia; Grupo C: Grupos A+B. A cada 30 dias, eles tinham amostra de sebo da fronte coletada para análise cromatográfica dos ácidos graxos nele presentes. Resultados: Quarenta sujeitos de pesquisa (88,9%) concluíram o estudo, os quais ingeriram todas as doses dos produtos, sem apresentarem eventos adversos em qualquer dos Grupos. O número de comedões, pústulas e cistos reduziu com o tempo (p<0,001, para todos), nos três Grupos. Com relação ao número total de lesões, houve uma maior quantidade de lesões em pacientes do Grupo B, quando comparados aos do Grupo A (p=0,033) e aos do Grupo C (p=0,030). Sete ácidos graxos apresentaram mudanças de seu padrão durante o estudo. De um modo geral, as mudanças que se tornaram mais evidentes foram: 1) a concentração de esqualeno no SB não reduziu em qualquer Grupo de estudo; 2) C12:0, C14:0 e C16:1 tiveram suas respectivas concentrações aumentadas nos três Grupos com o tempo de terapêuticas; 3) há indicativo de aumento de C18:1n9c+C18:1n9t na associação das duas classes terapêuticas estudadas; 4) limeciclina e/ou ingestão de ácido linoleico não aumentaram a participação do ácido linoleico no sebo; 5) ácido -linolênico teve sua concentração aumentada e, depois diminuída com o uso de LM e/ou com sua própria suplementação oral. Conclusões: A administração diária de limeciclina e/ou ácidos gamalinolênico, linoleico e oleico pode alterar o comportamento de alguns dos ácidos graxos presentes no sebo de pacientes portadores de acne vulgar graus II ou III. Os ácidos gamalinolênico, linoleico e oleico, se no uso sistêmico, não são considerados agentes terapêuticos na abordagem da acne; mais estudos precisam ser realizados a fim de se inferir a existência de possível benefício clínico de seu uso isolado e/ou associado na abordagem desta dermatose / Introduction: Acne is a dermatosis that presents an altered sebum pattern, quantitatively and qualitatively. Objectives: To study the possible quantitative and qualitative changes of fatty acids found in the sebum of patients with acne vulgaris grade II or III, through the daily use of lymecycline and/or oral supplementation based on linoleic, gamma-linolenic, and oleic acids. Methods: Fortyfive male research subjects, ages 12 to 40, presenting acne vulgaris grade II or III, were submitted to a 90-day use of: Group 1, 300mg of lymecycline per day; Group 2, 540mg of gamma-linolenic acid, 1,200mg of linoleic acid, and e 510mg of oleic acid per day; Group 3: Groups A+B. Every 30 days, a sample of the sebum of their forehead was collected for chromatographic analysis of the fatty acids contained therein. Results: Forty research subjects (88.9%) concluded the study. They ingested all dosages of the products, without presenting side effects in any of the Groups. The number of comedones, pustules, and cysts reduced with time (p<0.001, for all), in all the 3 Groups. With respect to the total number of lesions, Group B´s patients presented a larger quantity of lesions, as compared to those of Group A (p=0.033) and Group C (p=0.030). Seven fatty acids presented pattern changes during the study. In general, the changes that became more evident were: 1) the squalene concentration in the sebum did not diminish in any Group under study; 2) C12:0, C14:0, and C16:1 had their respective concentrations increased in the 3 Groups over the time of the treatments; 3) there is an indication for increasing of C18:1n9t+C18:1n9c when both of therapies are associated; 4) lymecycline and/or the ingestion of linoleic acid did not increase the participation of linoleic acid in the sebum; and 5) gama-linolenic acid had its concentration increased during the first 60-day and diminished during the last 30-day therapies period using lymecycline and/or with its own oral supplementation. Conclusions: The daily administration of lymecycline and/or gamma-linolenic, linoleic, and oleic acids may alter the behavior of some fatty acids present in the sebum of patients with acne vulgaris grade II or III. Gamma-linolenic, linoleic, and oleic acids, under systemic use, are not considered therapeutic agents in the treatment of acne; more studies need to be carried out in order to infer the existence of a possible clinical benefit of their isolated use and/or association in the treatment of this dermatosis

There is growing public concern about the high proportion of saturated fatty acids in milk fat; however, feed intake, energy partitioning toward milk synthesis, and milk fat concentrations can decrease when cows are fed high concentrations of unsaturated lipids. The objective of this study was to identify the optimal rate for feeding OmegaBoostTM (a flaxseed supplement that was processed using a proprietary technique by Double Pass LLC, Tualatin, OR) to dairy cows. The central hypothesis was that supplementation with OmegaBoost will decrease the proportion of saturated fatty acids in milk fat in a dose dependent manner. Using a latin-square design, 10 Holstein cows in mid to late lactation were fed for two-week periods 0, 2, 4, or 6 lbs/d of OmegaBoost or 4lbs/d ground flax as top dressing to their total mixed ration. Feed intake, body weight, activity and resting time, milk production and milk composition were measured daily. At the end of each two-week period, milk and serum samples were taken and analyzed for fatty acid composition using gas chromatography. In addition, fresh Mozzarella cheese and butter was manufactured and tested to determine the fatty acid composition and the effects of flaxseed supplementation on texture. Feeding OmegaBoost at 2, 4, and 6 lbs/d linearly decreased the proportion of saturated fatty acids in milk by 6, 15, and 18%, respectively, and linearly increased the proportion of mono-unsaturated fatty acids (14, 32, and 35%), poly-unsaturated fatty acids (16, 49, and 82%), and α-linolenic acid (26, 52, and 70%). Similar changes in fatty acid composition were observed in butter and cheese samples, resulting in butter that was less hard and adhesive at refrigeration temperature in response to feeding cows increasing concentrations of OmegaBoost. Feed intake, body weight, serum metabolite concentrations, milk production and composition, and butter and cheese yield were not significantly affected by feeding processed flaxseed. Therefore, feeding 4 or 6 lbs/d of OmegaBoost to dairy cows is effective in improving the nutritional and textural profile of dairy products without negatively affecting feed intake, milk production, or weight gain. / Graduation date: 2012

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / The objective of the present work was to evaluate the effect of dietary linseed oil with or without injection of sodium selenite upon fatty acid profile and oxidative stability of milk from dairy cows as well as the acceptance of the milk and the increasing order of preference by the evaluators. Chapter 1 describes the experiment where fourteen cows were allocated into four treatments: Group 1 which received daily 400 mL of linseed oil (LIN); Group 2, 400 mL of linseed oil + 0.2 mg/BW sodium selenite IM (LINSe); Group 3, untreated controls (C). The oil was supplied daily after 15 days of de single application of sodium selenite. Treatments lasted 4 weeks. Linseed oil supplemented animals produced milk with higher levels of conjugated linoleic acid and omega 3 but also more susceptible to oxidation. The application of sodium selenite was effective to prevent premature oxidation of milk. Chapter 2 describes the acceptance and increasing order of preference by the evaluators. The evaluators were not able to identify differences in color, odor and flavor among samples of milk from treated and control groups in relation to a known standard. The inclusion of linseed oil on the cows diet promotes and increase in CLA and omega 3 in milk, which in turn becomes more susceptible to oxidation, requiring the use of antioxidants. Even though causing biochemicals alterations, the addition of 400 mL daily of linseed oil in the diet of dairy cows is not capable of causing sensory changes in milk. / O presente trabalho descreve as avaliações feitas no leite de vacas leiteiras submetidas a suplementação com óleo de linhaça na dieta, com ou sem injeção de selenito de sódio, quanto ao perfil de ácidos graxos, estabilidade oxidativa e em relação às propriedades organolépticas do leite. O capítulo 1 descreve o experimento em que catorze vacas foram distribuídas em três tratamentos: Grupo 1, que recebeu diariamente 400 mL de óleo de linhaça (LIN); Grupo 2, 400 mL de óleo de linhaça + 0,2 mg / Kg de selenito de sódio IM (LINSe) e Grupo 3 controles não tratados (C). O óleo foi fornecido diariamente após 15 dias da aplicação única de selenito de sódio, e o experimento teve duração de quatro semanas. Foram feitas análises do perfil de ácidos graxos e de reações ao ácido tiobarbitúrico, que mede a estabilidade oxidativa do produto. Os animais suplementados com o óleo de linhaça produziram leite com altos níveis de ácido linoleico conjugado e de ômega 3, contudo, mais suscetível à oxidação. A aplicação injetável de selenito de sódio mostrou-se eficaz ao impedir a oxidação prematura do leite. O capítulo 2 descreve o experimento onde se verificou a aceitação e a ordem crescente de preferência pelos avaliadores, de amostras de leite, através de análises de cor, odor e sabor. Catorze vacas foram distribuídas em três tratamentos: Grupo 1, que recebeu diariamente 400 mL de óleo de linhaça (LIN), Grupo 2, 400 mL de óleo de linhaça + 0,2 mg /Kg de selenito de sódio IM (LINSe) e Grupo 3 controles não tratados (C). O óleo foi fornecido diariamente após 15 dias da aplicação única de selenito de sódio, e o experimento teve duração de dez semanas. O resultado deste estudo foi de que os avaliadores não foram capazes de identificar diferenças de cor, odor e sabor entre as amostras de leite dos grupos tratados e do controle, em relação a um padrão conhecido. Assim, concluiu-se que a inclusão do óleo de linhaça na dieta de vacas leiteiras resulta em aumento do CLA, ômega 3 e consequentemente da oxidação do leite, necessitando assim o uso de substâncias antioxidantes ou promotores antioxidantes, como o selenito de sódio injetável para retardar a oxidação. Entretanto, a inclusão de 400 mL diários de óleo de linhaça na dieta de vacas leiteiras não é capaz de provocar alterações sensoriais no leite.

Introdução: Acne é uma dermatose que apresenta o padrão do sebo alterado, tanto quali, quanto quantitativamente. Objetivos: Estudar as possíveis alterações quali e quantitativas dos ácidos graxos encontrados no sebo de portadores de acne vulgar graus II ou III mediante ao uso diário de limeciclina e/ou suplemento oral a base de ácidos linoleico, gamalinolênico e oleico. Métodos: Quarenta e cinco sujeitos de pesquisa masculinos, de 12 a 40 anos de idade, portadores de acne vulgar graus II ou III, submeteram-se a 90 dias de uso de: Grupo A, 300mg/dia de limeciclina; Grupo B, 540mg de ácidos gamalinolênico, 1.200mg linoleico e 510mg oleico/dia; Grupo C: Grupos A+B. A cada 30 dias, eles tinham amostra de sebo da fronte coletada para análise cromatográfica dos ácidos graxos nele presentes. Resultados: Quarenta sujeitos de pesquisa (88,9%) concluíram o estudo, os quais ingeriram todas as doses dos produtos, sem apresentarem eventos adversos em qualquer dos Grupos. O número de comedões, pústulas e cistos reduziu com o tempo (p<0,001, para todos), nos três Grupos. Com relação ao número total de lesões, houve uma maior quantidade de lesões em pacientes do Grupo B, quando comparados aos do Grupo A (p=0,033) e aos do Grupo C (p=0,030). Sete ácidos graxos apresentaram mudanças de seu padrão durante o estudo. De um modo geral, as mudanças que se tornaram mais evidentes foram: 1) a concentração de esqualeno no SB não reduziu em qualquer Grupo de estudo; 2) C12:0, C14:0 e C16:1 tiveram suas respectivas concentrações aumentadas nos três Grupos com o tempo de terapêuticas; 3) há indicativo de aumento de C18:1n9c+C18:1n9t na associação das duas classes terapêuticas estudadas; 4) limeciclina e/ou ingestão de ácido linoleico não aumentaram a participação do ácido linoleico no sebo; 5) ácido -linolênico teve sua concentração aumentada e, depois diminuída com o uso de LM e/ou com sua própria suplementação oral. Conclusões: A administração diária de limeciclina e/ou ácidos gamalinolênico, linoleico e oleico pode alterar o comportamento de alguns dos ácidos graxos presentes no sebo de pacientes portadores de acne vulgar graus II ou III. Os ácidos gamalinolênico, linoleico e oleico, se no uso sistêmico, não são considerados agentes terapêuticos na abordagem da acne; mais estudos precisam ser realizados a fim de se inferir a existência de possível benefício clínico de seu uso isolado e/ou associado na abordagem desta dermatose / Introduction: Acne is a dermatosis that presents an altered sebum pattern, quantitatively and qualitatively. Objectives: To study the possible quantitative and qualitative changes of fatty acids found in the sebum of patients with acne vulgaris grade II or III, through the daily use of lymecycline and/or oral supplementation based on linoleic, gamma-linolenic, and oleic acids. Methods: Fortyfive male research subjects, ages 12 to 40, presenting acne vulgaris grade II or III, were submitted to a 90-day use of: Group 1, 300mg of lymecycline per day; Group 2, 540mg of gamma-linolenic acid, 1,200mg of linoleic acid, and e 510mg of oleic acid per day; Group 3: Groups A+B. Every 30 days, a sample of the sebum of their forehead was collected for chromatographic analysis of the fatty acids contained therein. Results: Forty research subjects (88.9%) concluded the study. They ingested all dosages of the products, without presenting side effects in any of the Groups. The number of comedones, pustules, and cysts reduced with time (p<0.001, for all), in all the 3 Groups. With respect to the total number of lesions, Group B´s patients presented a larger quantity of lesions, as compared to those of Group A (p=0.033) and Group C (p=0.030). Seven fatty acids presented pattern changes during the study. In general, the changes that became more evident were: 1) the squalene concentration in the sebum did not diminish in any Group under study; 2) C12:0, C14:0, and C16:1 had their respective concentrations increased in the 3 Groups over the time of the treatments; 3) there is an indication for increasing of C18:1n9t+C18:1n9c when both of therapies are associated; 4) lymecycline and/or the ingestion of linoleic acid did not increase the participation of linoleic acid in the sebum; and 5) gama-linolenic acid had its concentration increased during the first 60-day and diminished during the last 30-day therapies period using lymecycline and/or with its own oral supplementation. Conclusions: The daily administration of lymecycline and/or gamma-linolenic, linoleic, and oleic acids may alter the behavior of some fatty acids present in the sebum of patients with acne vulgaris grade II or III. Gamma-linolenic, linoleic, and oleic acids, under systemic use, are not considered therapeutic agents in the treatment of acne; more studies need to be carried out in order to infer the existence of a possible clinical benefit of their isolated use and/or association in the treatment of this dermatosis

Diabetes mellitus tipo 2 (DM2) está associado a um estado de inflamação crônica e ativação do estresse do retículo endoplasmático (ERE). Nesse contexto, são necessários estudos para encontrar alternativas que melhorem o quadro inflamatório, como os ácidos graxos poli-insaturados ômega 3 (n-3 PUFA), um conhecido agente anti-inflamatório. Esse estudo teve por objetivo avaliar o efeito da suplementação do ácido alfa-linolênico (ALA, um n-3 PUFA) no estresse do retículo endoplasmático e no estado inflamatório no tecido adiposo subcutâneo abdominal (TASC) em pacientes com DM2. Foi conduzido um estudo duplo-cego, prospectivo, placebo-controlado. Vinte pacientes com DM2 foram randomizados para suplementação com 3g/dia de ALA ou placebo durante 60 dias. O tecido adiposo foi coletado através de punção aspirativa por agulha fina do abdome antes e após a suplementação e os genes e proteínas foram avaliados através de PCR em tempo real e western blot. Foi encontrada, após suplementação, uma redução da expressão gênica do XBP1 (20%), sXBP1 (70%) e aumento da expressão gênica do GRP78 (150%), confirmado na expressão proteica. Além disso, foi encontrado aumento da expressão gênica da adiponectina (90%) e redução da expressão gênica do IL-6 (80%) e IRS-1 (60%), sem correlação com a expressão proteica, no tempo pós-suplementação com ALA. Portanto, foi demonstrado que o ALA pode modular o ERE através da via da IRE1/XBP, levando ao aumento das chaperonas (BIP/GRP78), além de um efeito adicional na expressão gênica da adiponectina, IL-6 e IRS-1, o que pode demonstrar um potencial terapêutico do ALA em pacientes com DM2. / Type 2 diabetes mellitus (T2DM) is a state of chronic inflammation and activation of endoplasmic reticulum stress (ERS). In this context, studies are necessaries to find new possibilities to improve this inflammation such as the n-3 polyunsaturated fatty acid (n-3 PUFA) acting as an anti-inflammatory agent. In this study, we aimed to evaluate the effect of n-3 PUFA alpha-linolenic acid (ALA, a n-3 PUFA) supplementation in T2DM patients on the molecular expression of ERS genes in abdominal subcutaneous adipose tissue (SAT). We performed a placebo-controlled study, in a double-blind design with 20 T2DM patients, receiving, randomly, 3g/day of ALA or placebo for 60 days. The adipose tissue was collected by fine-needle aspiration in abdomen before and after the supplementation and the genes and proteins were evaluated by real-time PCR and western blot. It was seen, after the supplementation, a reduction in XBP1 (20%), sXBP1 (70%) and an increase in Grp78 (150%) gene expression, likewise same results in protein concentration. Furthermore, it was observed an increase in adiponectina (90%) gene expression and reduction in IL-6 (80%) and IRS-1 (60%) gene expression, with no correlation to protein expression after supplementation of ALA. Therefore, we have provided evidence that ALA may modulate ERS by the IRE1/XBP pathway leading to an increase in chaperones (BIP/GRP78), additionally its effect on adiponectina, IL-6 and IRS-1 gene expression can demonstrate a therapeutic potential in T2DM.

Os gliomas são tumores cerebrais intracraniais caracterizados pelo seu rápido crescimento e pela sua resistência à quimioterapia e radioterapia atuais. Assim, a procura por novos agentes terapêuticos com múltiplos mecanismos de ação têm identificado o ácido <font face=\"symbol\">g-linolênico (GLA), antiinflamatórios não esteroidais (AINEs) e compostos contendo rutênio como possíveis candidatos. Dessa forma, a principal proposta deste projeto foi entender melhor o mecanismo de ação dessas drogas sobre as células C6 de glioma de rato. Foram analisadas proteínas envolvidas no controle do ciclo celular, apoptose, angiogênese, invasão e migração através de RT-PCR e Western Blotting após tratamento in vitro e in vivo. Alterações da expressão de ciclina D1, E2F-1, pRb, p27, p21, p16, p65, c-myc, ERK1/2, nm23 e <font face=\"symbol\">b, MMP-2, Brevican GPI e Secretado, Tenascina-R, Tenascina-C, VEGF-A, Flt1, Flk1, Bax, PPAR<font face=\"symbol\">g, p53, COX-2, EP1, 2, 3 e 4, Ku70 e 80 foram encontradas. Em conclusão, o GLA e o complexo Rutênio-Ibuprofeno possuem múltiplos alvos que levam à inibição da proliferação celular. / Gliomas are intracranial tumors of cerebral origin characterized for its rapid growth and resistance to both conventional chemotherapy and radiotherapy. The search for new therapeutics agents with multiple mechanisms of action has identified <font face=\"symbol\">g-linolenic acid (GLA), nonsteroidal anti-inflammatory drugs (NSAIDs) and ruthenium containing compounds as possible candidates. The aim of this study was to better know the mechanism of action of these drugs on C6 rat glioma cells. Expression of proteins involved in control of the cell cycle, apoptosis, angiogenesis, invasion and migration was analyzed using RT-PCR and Western Blotting methods after treatment in vitro and in vivo. Alterations in cyclin D1, E2F-1, pRb, p27, p21, p16, p65, c-myc, ERK1/2, nm23 e <font face=\"symbol\">b, MMP-2, GPI and Secreted Brevican, Tenascin-R, Tenascin-C, VEGF-A, Flt1, Flk1, Bax, PPAR<font face=\"symbol\">g, p53, COX-2, EP1, 2, 3 and 4, Ku70 and 80 expression were observed. In conclusion, GLA and Ruthenium-Ibuprofen complex has multiple target wich translate into the inhibition of proliferation.

Os gliomas são tumores cerebrais intracraniais caracterizados pelo seu rápido crescimento e pela sua resistência à quimioterapia e radioterapia atuais. Assim, a procura por novos agentes terapêuticos com múltiplos mecanismos de ação têm identificado o ácido <font face=\"symbol\">g-linolênico (GLA), antiinflamatórios não esteroidais (AINEs) e compostos contendo rutênio como possíveis candidatos. Dessa forma, a principal proposta deste projeto foi entender melhor o mecanismo de ação dessas drogas sobre as células C6 de glioma de rato. Foram analisadas proteínas envolvidas no controle do ciclo celular, apoptose, angiogênese, invasão e migração através de RT-PCR e Western Blotting após tratamento in vitro e in vivo. Alterações da expressão de ciclina D1, E2F-1, pRb, p27, p21, p16, p65, c-myc, ERK1/2, nm23 e <font face=\"symbol\">b, MMP-2, Brevican GPI e Secretado, Tenascina-R, Tenascina-C, VEGF-A, Flt1, Flk1, Bax, PPAR<font face=\"symbol\">g, p53, COX-2, EP1, 2, 3 e 4, Ku70 e 80 foram encontradas. Em conclusão, o GLA e o complexo Rutênio-Ibuprofeno possuem múltiplos alvos que levam à inibição da proliferação celular. / Gliomas are intracranial tumors of cerebral origin characterized for its rapid growth and resistance to both conventional chemotherapy and radiotherapy. The search for new therapeutics agents with multiple mechanisms of action has identified <font face=\"symbol\">g-linolenic acid (GLA), nonsteroidal anti-inflammatory drugs (NSAIDs) and ruthenium containing compounds as possible candidates. The aim of this study was to better know the mechanism of action of these drugs on C6 rat glioma cells. Expression of proteins involved in control of the cell cycle, apoptosis, angiogenesis, invasion and migration was analyzed using RT-PCR and Western Blotting methods after treatment in vitro and in vivo. Alterations in cyclin D1, E2F-1, pRb, p27, p21, p16, p65, c-myc, ERK1/2, nm23 e <font face=\"symbol\">b, MMP-2, GPI and Secreted Brevican, Tenascin-R, Tenascin-C, VEGF-A, Flt1, Flk1, Bax, PPAR<font face=\"symbol\">g, p53, COX-2, EP1, 2, 3 and 4, Ku70 and 80 expression were observed. In conclusion, GLA and Ruthenium-Ibuprofen complex has multiple target wich translate into the inhibition of proliferation.

Human skin has distinct lipid metabolism and production of bioactive lipid mediators that can be modulated by nutritional supplementation with omega-3 polyunsaturated fatty acids (n-3 PUFA), of which eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids exert anti-inflammatory effects. The aims of this project were to gain better understanding of their individual mechanisms in human epidermis and dermis. HaCaT keratinocytes, 46BR.1N fibroblasts, primary human epidermal keratinocytes and dermal fibroblasts were treated with EPA or DHA for 72h and then sham-irradiated or exposed to 15 mJ/cm2 ultraviolet radiation (UVR). Viability was measured by the MTT assay. The expression of cyclooxygenase-2 (COX-2), microsomal prostaglandin synthase-1 (mPGES-1) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) proteins was explored by western blotting. Human skin explants (n=4 donors) were cultured for 3 or 6 days and supplemented with EPA, DHA or vehicle. Culture media were collected to evaluate tissue damage and PUFA cytotoxicity (lactate dehydrogenase assay). Epidermal and dermal lipid profiles were assessed by gas chromatography and liquid chromatography coupled to tandem mass spectrometry. Primary keratinocytes were treated with fatty acids and various lipid mediators for 48h. Their effect was determined by the scratch assay and transepithelial electrical resistance. UVR upregulated COX-2 in HaCaT and primary epidermal keratinocytes, but did not affect mPGES-1 and 15-PGDH protein expression. UVR upregulated COX-2 and mPGES-1 in 46BR.1N fibroblasts but had no effect on 15-PGDH expression. The same UVR dose did not alter the expression of COX-2, mPGES-1 and 15-PGDH in primary dermal fibroblasts. Only EPA attenuated COX-2 expression in HaCaT and primary keratinocytes and either EPA or DHA had any effect in 46BR.1N and primary fibroblasts. Skin explants showed initial post-biopsy tissue damage. EPA and DHA supplementation augmented cellular levels of the corresponding fatty acids in both epidermis and dermis to a different extent. Increased uptake of DHA in the dermis was accompanied by reduced arachidonic acid levels. EPA treatment stimulated the production of PGE3 and various HEPE in epidermis, while DHA treatment caused high levels of HDHA species in dermis. N-3 PUFA and their derivatives delayed wound healing, cell migration and epidermal barrier permeability, while n-6 PUFA lipids showed the opposite effect. Overall, these findings suggest that EPA and DHA differently affect skin cells and skin, with EPA preference in epidermis and DHA in the dermis. These results highlight the importance of differential skin responses that could be important in skin health and disease.

No description available.

Background Iron deficiency (ID) is the world‟s most prevalent micronutrient deficiency and predominantly affects developing countries, also South Africa. In areas with low fish consumption and high n-6 PUFA vegetable oil intake, there is a risk for having inadequate n-3 PUFA status. Both iron and n-3 PUFA play important roles in the immune response, and supplementation is a strategy to alleviate deficiencies. However, little is known about potential interactive effects between concurrent iron and n-3 PUFA supplementation on the immune system. This is also important in the context that iron supplementation may be unsafe and may increase morbidity and mortality. Aim The overall aim of this thesis was to assess the effects of iron and docosahexaenoic (DHA)/eicosapentaenoic acid (EPA) supplementation, alone and in combination, on the immune system of ID children. More specifically, these effects were investigated on the occurrence and duration of illness and school-absenteeism due to illness, peripheral blood mononuclear cell (PBMC), red blood cell (RBC) and plasma total phospholipid fatty acid composition, iron status, fatty acid-derived immune modulators and targeted PBMC gene expression. Furthermore, association of PBMC, RBC and plasma total phospholipid fatty acid composition with allergic disease, were also examined. Design In a 2-by-2 factorial, randomised, double-blind, placebo-controlled trial, South African children (n = 321, aged 6–11 y) were randomly assigned to receive oral supplements of either 1) iron (50 mg as ferrous sulphate) plus placebo; 2) DHA/EPA (420/80 mg) plus placebo; 3) iron plus DHA/EPA (420/80 mg); or 4) placebo plus placebo for 8.5 mo, four times per week. Absenteeism and illness symptoms were recorded and biochemical parameters for compliance as well as parameters fundamental to immune function were assessed at baseline and endpoint. Furthermore, in a cross-sectional design, associations of allergic disease with baseline fatty acid composition of PBMC, RBC and plasma were examined. Results The combination of iron and DHA/EPA significantly attenuated respiratory illness caused by iron supplementation. DHA/EPA supplementation alone improved respiratory symptoms at school, but increased headache-related absenteeism. DHA/EPA and iron supplementation individually tended to increase and decrease anti-inflammatory DHA and EPA-derived mediators, respectively. Furthermore the anti-inflammatory DHA-derived immune mediator, 17HDHA was higher in the DHA/EPA plus placebo and iron plus DHA/EPA groups than in the iron plus placebo group. Also, the pro-inflammatory arachidonic acid (AA)-derived modulators (5- and 15-hydroxyeicosapentaenoic acid) were significantly lower in the iron plus DHA/EPA group compared to the placebo plus placebo groups. In the study population, 27.2% of the children had allergic disease and AA in PBMC phospholipids was significantly lower in the allergic children than in the non-allergic children. In RBC phospholipids dihomo-gamma-linolenic acid (DGLA) and the ratio of DGLA: linoleic acid (LA) correlated negatively and the n-6:n-3 PUFA ratio positively with total immunoglobulin E (tIgE). Furthermore, trans-C18:1n-9, tended to be higher in the allergic group. Conclusion DHA/EPA prevented respiratory illness caused by iron supplementation and although DHA/EPA on its own reduced respiratory morbidity when the children were present at school, surprisingly it increased the likelihood of being absent with headache and fever. The biochemical findings compliment the clinical results and support previous observations about DHA/EPA supplementation to reduce inflammation, but add to the current knowledge base that a relatively high oral dose of non-haem iron modulates circulating lipid-derived immune modulators and related gene expression. Furthermore, when supplementing with iron and DHA/EPA combined, in this ID population with low fish intake, the anti-inflammatory effect of DHA/EPA is maintained concurrently with attenuation of respiratory morbidity. This finding support the notion that excess iron (probably as non-transferrin bound iron) becomes available for pathogens and is probably why we found that iron increased respiratory infectious morbidity. The improved clinical outcome with combined supplementation seems to be related to increased lipid-mediator synthesis gene expression and the availability of DHA/EPA, leading to a more pro-resolving profile and enhanced immune competence. Overall these results give better insight into immune function and infectious morbidity in relation to n-3 PUFA and iron status and treatment, as well as the possible association of fatty acid status with allergic disease in young South-African school children. / PhD (Nutrition), North-West University, Potchefstroom Campus, 2015